OS Advantage of Gotistobart Over Docetaxel in Patients with anti-PD‑(L)1- and Chemotherapy-Resistant Metastatic Squamous NSCLC By Ogkologos - April 14, 2026 125 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the stage 1 of the phase III PRESERVE-003 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer August 20, 2018 EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises... December 22, 2020 Load more HOT NEWS Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... Diagnosed 3 Weeks Before Her Wedding, She Finally Gets To Ring... SABCS 2021: New Research and Updates in Breast Cancer Treatment and... How MRI add-ons could accelerate the development of new treatments
